Cargando…
DGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy
Immunotherapy is moving to the forefront of cancer treatments owing to impressive durable responses achieved with checkpoint blockade antibodies and adoptive T-cell therapy. Still, improvements are necessary since, overall, only a small percentage of patients benefit from current therapies. Here, I...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335622/ https://www.ncbi.nlm.nih.gov/pubmed/28316970 http://dx.doi.org/10.3389/fcell.2017.00016 |